CAR-T Cell Therapy Research has 837 eligible papers in the latest 30-day evidence window, up 54% from the prior window, with representative work spanning Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis; Characterization of CAR-T cell factors that contribute to myeloid cell activation; and CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review.
CAR-T Cell Therapy Research shows 837 eligible recent papers and 829 commentary-ready papers in the current 30-day window, compared with 545 eligible papers in the prior window. The strongest evidence comes from 1 visible topic cluster and 8 representative papers.
CAR-T Cell Therapy Research recorded 837 eligible papers in the latest 30-day window, compared with 545 in the prior 30-day window, making the current snapshot up 54% from the prior window.
837 recent vs 545 prior eligible papersCAR-T cell therapy research contributes 837 eligible recent papers, including 829 papers with abstracts available for commentary.
837 papers in the leading clusterThe representative set includes Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis; Characterization of CAR-T cell factors that contribute to myeloid cell activation; CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review; Structure–Function Insights into Immune Receptors Drive Innovation in CAR-T Cell Therapy; and Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy. These papers anchor the page's claims and keep the brief tied to visible evidence.
8 representative papersCAR-T cell therapy research accounts for 837 eligible recent papers, including 829 commentary-ready papers in this evidence window.
837 recent eligible papersThe selected papers cover Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis; Characterization of CAR-T cell factors that contribute to myeloid cell activation; CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review; and Structure–Function Insights into Immune Receptors Drive Innovation in CAR-T Cell Therapy.
8 representative papersA recent paper from BMC Cancer in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Gene Therapy in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Biomolecules and Biomedicine in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Current Issues in Molecular Biology in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Journal of Translational Medicine in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Blood in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Cancer Research in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Frontiers in Immunology in the CAR-T cell therapy research evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.